Suppression of ASNS increases the potency of artemisinin in an NSCLC model in which artemisinin activates the ER-resident PERK, which reactivates ERK, phosphorylating ATF4, and nuclear ATF4 can enhance ASNS production [109]. Here, ATF4 is linked to non-small cell lung carcinoma.